DYCONEX AG has become part of the SO.MA.CI.S S.p.A. Group
COMPANY STATEMENT
As of 1st of August 2024 DYCONEX AG has become part of the SO.MA.CI.S S.p.A. Group.
We are pleased to announce that SOMACIS has successfully acquired the renowned Swiss company DYCONEX AG, specializing in printed circuit boards (PCBs) with a strong presence in the medical sector. This strategic acquisition marks a significant milestone in our ongoing commitment to expanding and diversifying our product offerings.
DYCONEX‘s expertise and high-quality PCB solutions are well-regarded within the medical industry. Their innovative technologies, including biocompatible PCBs, and customer-centric approach align perfectly with SOMACIS’s values and long-term goals. This acquisition will broaden our portfolio and enhance our capabilities to serve our clients across various sectors better.
With this integration, SOMACIS will leverage DYCONEX’s technical know-how and market position to deliver cutting-edge solutions and strengthen our overall presence. We are confident that this acquisition will drive growth and innovation, ultimately benefiting our customers and stakeholders.
We are excited about the opportunities this acquisition brings and look forward to a seamless integration process.
We would like to emphasize that SOMACIS’s strategy does not stop here. We are constantly evolving to ensure that our printed circuit boards remain at the forefront of innovation. Our commitment to providing cutting-edge solutions is unwavering, and we look forward to continuously advancing our technology to meet the ever-changing needs of our customers.
Brand
DYCONEX has been acquired for its outstanding global reputation and competencies. Therefore,
DYCONEX will keep its own brand and will serve as the future medical pillar of the SOMACIS group.
Web and E-Mail addresses
The new website for DYCONEX is www.dyconex.com.
Our E-Mail domain will change from @mst.com to @dyconex.com – however, our old e-mail addresses
will remain valid until the 31st of October 2024.
